How India Exports Pseudoephedrine to the World

In the United States, pseudoephedrine is regulated by the Food and Drug Administration (FDA) and is available both over-the-counter (OTC) and by prescription, depending on the formulation. As of February 2026, the FDA approved Abbreviated New Drug Application (ANDA) 218854 for Pseudoephedrine Hydrochloride Extended-Release Tablets USP, 240 mg (OTC), submitted by Aurobindo Pharma USA, Inc., a subsidiary of Aurobindo Pharma Limited. This approval underscores the FDA's commitment to ensuring the availability of safe and effective generic medications.

The Combat Methamphetamine Epidemic Act of 2005 imposes strict regulations on the sale of pseudoephedrine-containing products in the U.S., including purchase limits and identification requirements, to prevent their misuse in methamphetamine production. These regulations necessitate that Indian exporters comply with stringent documentation and quality standards to access the U.S. market. The presence of 17 active Indian exporters indicates a robust engagement with these regulatory requirements, reflecting the industry's adaptability and commitment to compliance.

In the European Union (EU) and the United Kingdom (UK), pseudoephedrine is subject to comprehensive regulatory oversight. The European Medicines Agency (EMA) has approved products like Aerinaze, which combines desloratadine and pseudoephedrine, for the symptomatic treatment of seasonal allergic rhinitis with nasal congestion. This approval, granted in July 2007, highlights the established therapeutic use of pseudoephedrine in the EU. (ema.europa.eu)

In February 2023, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) initiated a safety review of pseudoephedrine-containing medicines due to concerns about rare cases of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS). This ongoing review may lead to changes in marketing authorizations, emphasizing the need for exporters to stay informed about evolving regulatory landscapes. (ema.europa.eu)

Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for exporting pharmaceuticals to the EU and UK. These standards ensure product quality and safety, requiring Indian manufacturers to maintain rigorous quality control systems and undergo regular inspections.

As of the 23rd edition of the WHO Model List of Essential Medicines, published in July 2023, pseudoephedrine is not included. This exclusion indicates that while pseudoephedrine is widely used, it is not considered essential for basic health care needs by WHO standards. (who.int)

Pseudoephedrine formulations must comply with international pharmacopoeia standards, including those set by the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures the quality, efficacy, and safety of pharmaceutical products in global markets.

In India, pseudoephedrine is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for sale. This classification aims to control its distribution and prevent misuse. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines; however, pseudoephedrine is not currently listed under price control, allowing market-driven pricing.

For export purposes, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for pseudoephedrine shipments, ensuring that exports comply with national regulations and international obligations.

Pseudoephedrine is a well-established pharmaceutical ingredient with no active patents restricting its manufacture or sale. This lack of patent protection has led to a competitive market with multiple generic manufacturers, both in India and globally, contributing to its widespread availability and affordability.

In April 2024, New Zealand's Parliament passed the Misuse of Drugs (Pseudoephedrine) Amendment Act 2024, reclassifying pseudoephedrine as a Class C controlled drug. This legislative change allows cold and flu medicines containing pseudoephedrine to be sold without prescriptions in pharmacies, reversing previous restrictions imposed in 2011.

In February 2023, the EMA's PRAC initiated a safety review of pseudoephedrine-containing medicines due to concerns about rare cases of PRES and RCVS. This review underscores the importance of ongoing pharmacovigilance and may lead to regulatory changes affecting the availability and use of these medicines in the EU. (ema.europa.eu)

These developments highlight the dynamic nature of the regulatory environment surrounding pseudoephedrine, necessitating continuous monitoring and compliance by exporters to maintain market access and ensure public safety.

India's pharmaceutical industry, including the production of pseudoephedrine, heavily relies on Key Starting Materials (KSMs) imported from China. This dependency is significant, with approximately 60–70% of KSMs for various APIs sourced from China. The concentration of KSM production in China poses a strategic risk, as any disruption in Chinese supply chains can directly impact India's API manufacturing capabilities.

Recent events have highlighted this vulnerability. In September 2025, China implemented aggressive pricing strategies, reducing the prices of 41 APIs and KSMs by 40–50%. This move aimed to undercut Indian API manufacturers, making domestic production less competitive and increasing reliance on Chinese imports. Such market dynamics underscore the fragility of India's API supply chain, particularly for critical components like pseudoephedrine.

Our proprietary trade data indicates a high supplier concentration in India's pseudoephedrine exports. The top five exporters account for 89.5% of the total export value, with SUN PHARMACEUTICAL INDUSTRIES LIMITED alone contributing 27.9%. This concentration poses a significant single-source risk; any operational or regulatory issues affecting these key suppliers could disrupt the entire supply chain.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in November 2024, aiming to boost domestic API and KSM production. This initiative led to the inauguration of two greenfield plants producing essential molecules like Penicillin G and Clavulanic Acid. While these efforts are steps toward reducing import dependence, the impact on pseudoephedrine production remains to be seen.

Geopolitical tensions have further exacerbated supply chain vulnerabilities. In March 2026, the Strait of Hormuz crisis led to significant disruptions in global shipping routes, affecting approximately 20% of the world's daily oil supply. This crisis caused a sharp decline in maritime transit, with tanker traffic dropping by about 70% and over 150 ships anchoring outside the strait to avoid risks. Such disruptions have cascading effects on global supply chains, including the transportation of pharmaceutical ingredients.

Additionally, the U.S. Food and Drug Administration (FDA) has issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practice (cGMP). In February 2025, Indian API manufacturer Global Calcium received such a warning, highlighting ongoing quality concerns and the potential for supply disruptions due to regulatory actions.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for critical APIs and KSMs to build a more resilient supply chain.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains.

• Strengthen Quality Assurance: Implement robust quality control measures to ensure compliance with international standards, mitigating risks of regulatory actions.

• Develop Contingency Plans: Create comprehensive risk management strategies, including alternative shipping routes and emergency stockpiles, to address potential disruptions.

RISK_LEVEL: HIGH